In February, Novo Nordisk agreed to buy Catalent for $16.5 billion. The Federal Trade Commission has since requested more information from the companies as it reviews the deal, The Wall Street Journal reported May 3.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
